USE OF INTRAVITREAL BEVACIZUMAB AS A PREOPERATIVE ADJUNCT FOR TRACTIONAL RETINAL DETACHMENT REPAIR IN SEVERE PROLIFERATIVE DIABETIC RETINOPATHY

摘要

Bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) is an anti-vascular endothelial growth factor (VEGF) agent that has been approved by the US Food and Drug Administration as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. Recent reports on the intravitreal injection of bevacizumab show promise for targeting VEGF-implicated intraocular neovascularization seen in age-related macular degeneration and diabetic ret-inopathy. We report on the use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe active proliferative diabetic retinopathy.